Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD20 (Ofatumumab) in Active Rheumatoid Arthritis
NCT00291928Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ofatumumab in rheumatoid arthritis (RA), sponsored by GSK. Started Feb 2005; status: completed.
02
Drugs
ofatumumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00291928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291928.